TGF-β1 (Transforming Growth Factor Beta 1)

TGF-β1 (Transforming Growth Factor Beta 1) is a clinical biomarker on the Inflammation panel, reported in pg/mL. Standard reference range: 0–2380 pg/mL. Functional (optimal) range used by integrative practitioners: 0–1500 pg/mL.

What is TGF-β1 (Transforming Growth Factor Beta 1)?

TGF-β1 is a pleiotropic cytokine governing immune regulation (Treg expansion), tissue repair, and fibrogenesis. <strong>Tiered interpretation:</strong> >2,380 pg/mL = CIRS-consistent (correlate with C4a, MSH, MMP-9, VEGF, VIP); >10,000 pg/mL = markedly elevated (aggressive biotoxin immune activation); >20,000 pg/mL = severely elevated (severe CIRS or concurrent fibrotic disease — assess for IPF, CKD, hepatic cirrhosis, cardiac fibrosis, or malignancy). NOT CIRS-specific: also elevated in pulmonary fibrosis, CKD, Lyme, long COVID, autoimmune flares, and malignancy.

Reference ranges

How SomaVue interprets TGF-β1 (Transforming Growth Factor Beta 1)

SomaVue maps every result for TGF-β1 (Transforming Growth Factor Beta 1) against four clinical lenses — nutrient cofactors, toxin exposure, infection drivers, and circadian/hormonal context — and connects each interpretation to specific peer-reviewed citations. Pre-mapped clinical reasoning and cross-marker pattern detection are available inside the practitioner workspace.

Educational reference only. Reference ranges vary by laboratory, assay method, age, sex, and clinical context. Functional ranges represent integrative-medicine consensus and are not regulatory thresholds. SomaVue does not diagnose, treat, mitigate, or prevent disease. Always consult a licensed healthcare provider.